All In Biotech

Drug Trial Radar · NCT00963469

Montelukast in Seasonal Allergic Rhinitis: Fall 2001 Study (0476-240)

A Multicenter, Double-Blind, Randomized, Parallel-Group Study Investigating the Clinical Effect of Montelukast in Patients With Seasonal Allergic Rhinitis Over a 4-Week Treatment Period-Fall 2001

Last checked: Nov 19, 2026Latest source record: Feb 3, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,079 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,079

Actual

Start

Aug 2001

Primary completion

Nov 2001

Study completion Nov 2001

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Aug 21, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 15 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the treatment effect of montelukast 10 mg taken in the morning, versus placebo, in patients with seasonal allergic rhinitis. Loratadine is included in the study as an active control.

Conditions

  • Seasonal Allergic Rhinitis

Interventions

  • montelukast sodiumDrug

    montelukast 10 mg tablet orally once daily in the morning for 4 weeks

  • Comparator: loratadineDrug

    loratadine 10 mg tablet orally once daily in the morning for 4 weeks

  • Comparator: placeboDrug

    placebo tablet orally once daily in the morning for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Change From Baseline in Daytime Nasal Symptoms Score Over First 2 Weeks of Treatment PeriodTime frame: Baseline and first 2 Weeks of treatment period (from randomization through the end of Week 2)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.